The peripheral arterial disease subgroup in the CHARISMA trial: Does it tell us anything new?

European Heart Journal

Volumn 30, Issue 2, 2009, Pages 131-132

  Gresele, Paolo ^a   Migliacci, Rino ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b USL 8   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; EDITORIAL; EUROPE; HEART INFARCTION; HUMAN; MORTALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; UNITED STATES;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; PERIPHERAL VASCULAR DISEASES;

EID: 58449091288     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn565     Document Type: Editorial

References (14)

1. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease morbidity and mortality implications. Circulation 2006;114:688-699.
2. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-892.
3. Agnelli G, Cimminiello C, Meneghetti G, Urbinati S; the Polyvascular Atherothrombosis Observational Survey (PATHOS) Investigators. Low ankle-brachial index predicts adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb Haemost 2006;4:2599-2602.
4. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d'Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodríguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197-208.
5. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
6. Gresele P, Migliacci R. Extrapolation of trial results suggests that aspirin is useful in intermittent claudication. Br Med J 1998;317:1587-1588.
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
8. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-227.
9. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot J, Perason TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo I, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
10. Cacoub PP, Bhatt DL, Steg PG, Topol EJ. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009;30:192-201. doi:10.1093/eurheartj/ehn534.
11. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-1988.
12. Sevdalis N, Jacklin R. Interaction effects and subgroup analyses in clinical trials: more than meets the eye? J Eval Clin Pract 2008;14:919-922.
13. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008;118:1705-1712.
14. Sobel M, Verhaeghe R; American College of Chest Physicians; American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:815S-843S.